share_log

Aditxt | 8-K: Current report

Aditxt | 8-K: Current report

Aditxt | 8-K:重大事件
美股SEC公告 ·  09/07 04:22

Moomoo AI 已提取核心訊息

Aditxt, Inc., a biotech company, has announced amendments to its merger agreement with Evofem Biosciences, Inc. through a Current Report on Form 8-K filed with the SEC. The report, dated September 6, 2024, details the company's entry into Amendment No. 2 to the Amended and Restated Merger Agreement. This amendment adjusts the dates and amounts of the third and fourth equity investments Aditxt is making in Evofem. The third investment date has been changed from September 6, 2024, to September 30, 2024, with the investment amount reduced from $2 million to $1.5 million. The fourth investment date has been extended from September 30, 2024, to October 31, 2024, with the amount increased from $1 million to $1.5 million. The merger will result in Evofem becoming a wholly owned subsidiary of Aditxt. The report also includes a cautionary note on forward-looking statements and clarifies that this is not an offer to sell securities or a solicitation of an offer to buy any securities.
Aditxt, Inc., a biotech company, has announced amendments to its merger agreement with Evofem Biosciences, Inc. through a Current Report on Form 8-K filed with the SEC. The report, dated September 6, 2024, details the company's entry into Amendment No. 2 to the Amended and Restated Merger Agreement. This amendment adjusts the dates and amounts of the third and fourth equity investments Aditxt is making in Evofem. The third investment date has been changed from September 6, 2024, to September 30, 2024, with the investment amount reduced from $2 million to $1.5 million. The fourth investment date has been extended from September 30, 2024, to October 31, 2024, with the amount increased from $1 million to $1.5 million. The merger will result in Evofem becoming a wholly owned subsidiary of Aditxt. The report also includes a cautionary note on forward-looking statements and clarifies that this is not an offer to sell securities or a solicitation of an offer to buy any securities.
Aditxt公司,一家生物科技公司,已通過向美國證券交易委員會提交的8-k表中的《現行報告》宣佈了與evofem生命科學公司的合併協議的修訂。該報告日期爲2024年9月6日,詳細說明了公司與修訂和重新制定的合併協議的第二修正案的簽訂。該修正案調整了Aditxt對Evofem的第三和第四筆股權投資的日期和金額。第三筆投資日期從2024年9月6日更改爲2024年9月30日,投資金額從200萬美元降低至150萬美元。第四筆投資日期從2024年9月30日延長至2024年10月31日,金額由100萬美元增加至150萬美元。合併將使Evofem成爲Aditxt的全資子公司。該報告還包括關於前瞻性陳述的警示性說明,並澄清這不是出售證券或要約購買任何證券的要約。
Aditxt公司,一家生物科技公司,已通過向美國證券交易委員會提交的8-k表中的《現行報告》宣佈了與evofem生命科學公司的合併協議的修訂。該報告日期爲2024年9月6日,詳細說明了公司與修訂和重新制定的合併協議的第二修正案的簽訂。該修正案調整了Aditxt對Evofem的第三和第四筆股權投資的日期和金額。第三筆投資日期從2024年9月6日更改爲2024年9月30日,投資金額從200萬美元降低至150萬美元。第四筆投資日期從2024年9月30日延長至2024年10月31日,金額由100萬美元增加至150萬美元。合併將使Evofem成爲Aditxt的全資子公司。該報告還包括關於前瞻性陳述的警示性說明,並澄清這不是出售證券或要約購買任何證券的要約。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息